Skye Bioscience, Inc. Common Stock
Symbol: SKYE (NASDAQ)
4.14
▲ (0.12%) 0.005
Company Description:
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Key Stats
- Today's Open: $4.115
- Today's High: $4.164
- Today's Low: $4.09
- Today's Volume: 2.40K
- Yesterday Close: $4.13
- Yesterday High: $4.32
- Yesterday Low: $4.01
- Yesterday Volume: 340.61K
- Last Min Volume: 2.00K
- Last Min High: $4.135
- Last Min Low: $4.135
- Last Min VWAP: $4.135
Company Profile
- Name: Skye Bioscience, Inc. Common Stock
- Website: https://www.skyebioscience.com
- Listed Date: 2014-02-24
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001516551
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $127.98M
- Round Lot: 100
- Outstanding Shares: 30.99M
- Asset Type: CS
RECENT FILINGS FOR SKYE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-06-11 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-08 | 8-K | View |
| 2025-05-08 | 10-Q | View |
| 2025-04-25 | 3 | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-10 | SCHEDULE 13G/A | View |
| 2025-03-20 | S-8 | View |
| 2025-03-20 | 8-K | View |
| 2025-03-20 | 10-K | View |
| 2025-02-28 | 4/A | View |
| 2025-02-26 | 4 | View |
| 2025-02-26 | 4 | View |
Latest News on SKYE